Summary. Forty women with established menorrhagia were treated with either mefenamic acid (500 mg thrice daily for 3–5 days in two cycles) or danazol (100 mg twice daily for 60 days) in an open parallel group randomized study. Mefenamic acid reduced mean menstrual blood loss from 160ml to 127ml (20%, P<0·01). Danazol reduced mean menstrual loss from 163 ml to 65 ml (60%, P<0·001). The percentage reduction in menstrual blood loss was significantly greater in the danazol group than in the mefenamic acid group, but the adverse sideeffects occurred significantly more often in the danazol group (75%) than in the mefenamic acid group (30%, P<0–005). Overall, approximately half the women in each group were prepared to continue with the treatment they received to reduce their menstrual bleeding.

No abstract

No abstract

Summary. Menstrual fluid was obtained from the uterine cavity and vagina in 20 women within the first 48 h of menstruation. Ten of the women had normal menstrual cycles and blood loss and ten were patients with dysfunctional uterine bleeding. The menstrual samples were examined by electron microscopy for the presence of fibrin and platelets and nearly all were found to contain both fibrin and aggregating platelets. By a simple quantitative system no differences in fibrin and platelet content were found between samples collected from the uterine cavity or the vagina. Likewise no difference was found in the morphology of fibrin and platelets between women with normal menstrual loss and patients with dysfunctional uterine bleeding.